We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Report: FDA Should Set Deadlines to Review Postmarketing Studies
Report: FDA Should Set Deadlines to Review Postmarketing Studies
September 4, 2009
Drug and biologic makers are on schedule with most postmarketing studies, but while the FDA misses its review deadlines more than half the time, some criticism of its oversight is undeserved, a report says.